Access the full text.
Sign up today, get DeepDyve free for 14 days.
川畑 茂 (2002)
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells
(2005)
Association of the BCRP C 421 A polymorphism with nonpapillary renal cell carcinoma
Y. Korenaga, K. Naito, N. Okayama, H. Hirata, Y. Suehiro, Y. Hamanaka, H. Matsuyama, Y. Hinoda (2005)
Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinomaInternational Journal of Cancer, 117
K. Miyake, L. Mickley, T. Litman, Z. Zhan, R. Robey, Barbara Cristensen, Mariafiorella Brangi, L. Greenberger, Michael Dean, T. Fojo, S. Bates (1999)
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.Cancer research, 59 1
James Cuff, M. Clamp, A. Siddiqui, M. Finlay, G. Barton (1999)
JPred : a consensus secondary structure prediction server
S. Kawabata, M. Oka, Ken Shiozawa, K. Tsukamoto, K. Nakatomi, H. Soda, M. Fukuda, Y. Ikegami, K. Sugahara, Yasuaki Yamada, S. Kamihira, L. Doyle, Douglas Ross, S. Kohno (2001)
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.Biochemical and biophysical research communications, 280 5
Jing Li, G. Cusatis, J. Brahmer, A. Sparreboom, R. Robey, S. Bates, M. Hidalgo, S. Baker (2007)
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patientsCancer Biology & Therapy, 6
Yong-Fu Li, O. Polgar, Masaki Okada, L. Esser, S. Bates, D. Xia (2007)
Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study.Journal of molecular graphics & modelling, 25 6
C. Brendel, C. Scharenberg, M. Dohse, R. Robey, S. Bates, S. Shukla, S. Ambudkar, Y. Wang, G. Wennemuth, Andreas Burchert, U. Boudriot, A. Neubauer (2007)
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cellsLeukemia, 21
C. Lambert, Nadia Léonard, X. Bolle, E. Depiereux (2002)
ESyPred3D: Prediction of proteins 3D structuresBioinformatics, 18 9
(2000)
YC: BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells
R. Finn, Jaina Mistry, Benjamin Schuster-Böckler, S. Griffiths-Jones, Volker Hollich, T. Lassmann, Simon Moxon, M. Marshall, Ajay Khanna, R. Durbin, S. Eddy, E. Sonnhammer, A. Bateman (2005)
Pfam: clans, web tools and servicesNucleic Acids Research, 34
Mariafiorella Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo, S. Bates (1999)
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.Cancer research, 59 23
P. Houghton, G. Germain, F. Harwood, J. Schuetz, C. Stewart, E. Buchdunger, P. Traxler (2004)
Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in VitroCancer Research, 64
Gary Ewart, Anthony Howells (1998)
ABC transporters involved in transport of eye pigment precursors in Drosophila melanogaster.Methods in enzymology, 292
(2004)
Folate deprivation results in the loss of breast cancer resistance protein ( BCRP / ABCG 2 ) expression . A role for BCRP in cellular folate homeostasis
Anass Haimeur, G. Conseil, R. Deeley, S. Cole (2004)
The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.Current drug metabolism, 5 1
M. Maliepaard, G. Scheffer, I. Faneyte, M. Gastelen, A. Pijnenborg, A. Schinkel, M. Vijver, R. Scheper, J. Schellens (2001)
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.Cancer research, 61 8
(2000)
Methotrexate crossresistance in a mitoxantroneselected multidrugresistant MCF 7 breast cancer cell line is attributable to enhanced energydependent drug efflux
Yasumasa Honjo, C. Hrycyna, Qing-Wu Yan, Wilma Medina-Pérez, R. Robey, A. Laar, T. Litman, Michael Dean, S. Bates (2001)
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.Cancer research, 61 18
W. Fairbrother, Gene Yeo, R. Yeh, P. Goldstein, Matthew Mawson, P. Sharp, C. Burge (2004)
RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exonsNucleic acids research, 32 Web Server issue
E. Volk, Kate Farley, Yan Wu, Fei Li, R. Robey, E. Schneider (2002)
Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.Cancer research, 62 17
C. Lambert, Nadia Léonard, X. Bolle, Eric Depiereux, Facultés (2002)
ESyPred 3 D : Prediction of proteins 3 D structures
Yi Chen, L. Mickley, Arnold Schwartz, E. Acton, Jaulang Hwang, A. Fojo (1990)
Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein.The Journal of biological chemistry, 265 17
The multidrugresistant phenotype associated with overexpression of the new ABC halftransporter , MXR ( ABCG 2 )
R. Allikmets, L. Schriml, A. Hutchinson, Vincenzo, Romano-Spica, Michael, Dean (1998)
A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.Cancer research, 58 23
Kenneth To, Z. Zhan, S. Bates (2006)
Aberrant Promoter Methylation of the ABCG2 Gene in Renal CarcinomaMolecular and Cellular Biology, 26
W. Fairbrother, D. Holste, C. Burge, P. Sharp (2004)
Single Nucleotide Polymorphism–Based Validation of Exonic Splicing EnhancersPLoS Biology, 2
N. Sagara, M. Katoh (2000)
Mitomycin C resistance induced by TCF-3 overexpression in gastric cancer cell line MKN28 is associated with DT-diaphorase down-regulation.Cancer research, 60 21
Assaf Shafran, I. Ifergan, Eran Bram, G. Jansen, I. Kathmann, G. Peters, R. Robey, S. Bates, Y. Assaraf (2005)
ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.Cancer research, 65 18
I. Ifergan, Assaf Shafran, G. Jansen, J. Hooijberg, G. Scheffer, Y. Assaraf (2004)
Folate Deprivation Results in the Loss of Breast Cancer Resistance Protein (BCRP/ABCG2) ExpressionJournal of Biological Chemistry, 279
Ivica Letunic, R. Copley, Birgit Pils, Stefan Pinkert, J. Schultz, P. Bork (2005)
SMART 5: domains in the context of genomes and networksNucleic Acids Research, 34
C. Yang, Erasmus Schneider, Erasmus Schneider, Min-Liang Kuo, E. Volk, Emmanuelle Rocchi, Yao-Chang Chen (2000)
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.Biochemical pharmacology, 60 6
Karin Ejendal, N. Diop, Linda Schweiger, C. Hrycyna (2006)
The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate bindingProtein Science, 15
L. Doyle, Weidong Yang, L. Abruzzo, Tammy Krogmann, Y. Gao, A. Rishi, Douglas Ross (1998)
A multidrug resistance transporter from human MCF-7 breast cancer cells.Proceedings of the National Academy of Sciences of the United States of America, 95 26
(2002)
ESyPred3D: prediction of proteins
(1990)
Characterization of adriamycinresistant human breast cancer cells which display overexpression of a novel resistancerelated membrane protein
T. Litman, Mariafiorella Brangi, E. Hudson, P. Fetsch, A. Abati, Douglas Ross, K. Miyake, J. Resau, S. Bates (2000)
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).Journal of cell science, 113 ( Pt 11)
E. Volk, Kristin Rohde, M. Rhee, J. McGuire, L. Doyle, Douglas Ross, E. Schneider (2000)
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.Cancer research, 60 13
ABCG2 is a multidrug cellular transport protein that is associated with resistance to certain treatments in patients, particularly anticancer treatment. The tumor-protective properties of ABCG2 expression are reported to be a feature of a subset of stem cell-like tumor cells. While protection against chemotherapy has been well analyzed, the role of ABCG2 in the treatment with tyrosine kinase inhibitors is only partially understood. Tyrosine kinase inhibitors are currently the main treatment option in irresectable renal cell carcinomas. To investigate possible underlying sequence variations in the ABCG2 gene with relevance to the functional properties of the protein, 36 patient samples were analyzed. Using sequence analysis and single-nucleotide polymorphism databases, sequence variations in the highly conserved domains of the binding pocket of ABCG2 were analyzed. The resulting variations were used for computational protein prediction algorithms to identify conformational alterations. A relevant shift from A to G at position 1376 (resulting in Y→C at 459 aa) was identified and found to be present in 8.3% of the patients. These patients are currently in follow-up after resection, thus, further analysis will reveal whether this mutation has relevance to treatment efficacy.
Oncology Reports – Spandidos Publications
Published: May 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.